Editorial#1 States and the Danger of Poorly Manufactured Drugs
Context
The increasing instances of Not of Standard Quality (NSQ) drugs in India have raised significant concerns about drug quality and public health. A recent tragedy in Ballari, Karnataka, where five young mothers died allegedly due to contaminated drugs, underscores the urgency of addressing these challenges. The Union government must lead efforts to empower states and strengthen regulatory mechanisms to ensure drug safety across the nation.
Introduction
India’s pharmaceutical sector operates under the Drugs and Cosmetics Act, 1940, a framework that has unique regulatory features. Manufacturing licenses and inspections are conducted at the state level, but drugs produced in one state can be marketed across the country. This creates significant challenges for states like Karnataka, which are unable to prevent the inflow of substandard drugs manufactured in other states.
Data underscores this issue:
- Of the 894 samples tested in Karnataka over three years, 601 failing samples originated from manufacturers outside the state.
- States currently lack the authority to act against such manufacturers effectively.
Challenges in Ensuring Drug Quality
- Regulatory Limitations
- States are restricted to prosecuting pharmaceutical companies for NSQ drugs. Criminal proceedings are time-consuming, leaving states powerless to act immediately.
- Only drug inspectors from the home state of a manufacturer can suspend or cancel manufacturing licenses, limiting the ability of other states to intervene.
- Fragmented Information
- There is no mechanism for states to access a centralized database of test results, inspection reports, or licensing information.
- Procurement agencies like the Karnataka State Medical Supplies Corporation Ltd. (KSMSCL) have no means to verify the track record of pharmaceutical companies during tendering processes.
- Public Health Risks
- The lack of reliable information on drug quality affects procurement decisions, leading to scenarios such as Maharashtra’s recent spurious antibiotic scandal.
- Without robust checks, substandard drugs continue to endanger lives, eroding public trust in healthcare systems.
Proposed Solutions to Improve Drug Quality
- Enhanced Information Sharing
- Create a centralized database of drug test results from all state and central laboratories.
- This would enable drug inspectors and procurement officials nationwide to track the performance of pharmaceutical companies and adopt a risk-based approach to enforcement.
- Centralized Database of Inspection and Licensing Records
- A unified platform should consolidate inspection reports and licensing data for manufacturers across states.
- This would allow procurement agencies to assess the inspection standards of different states and prioritize sourcing drugs from manufacturers with rigorous oversight.
- Central Register for Blacklisted Manufacturers
- Establish a centralized register of pharmaceutical companies blacklisted for NSQ drugs.
- Procurement agencies could verify claims of compliance made by companies during tenders, ensuring accountability and improving drug quality.
- Empowering States with Legal Authority
- Amend the Drugs and Cosmetics Act, 1940 to grant states the power to block the sale of drugs from external manufacturers under investigation for serious lapses.
- Manufacturers should be required to demonstrate compliance before resuming operations in the affected state.
Role of the Union Government
Given that drug regulation is governed by central legislation, the Union Ministry of Health must spearhead reforms. States like Karnataka can provide constructive support to ensure the implementation of measures that enhance drug quality nationwide.
Conclusion
India’s public health infrastructure depends on the availability of safe, high-quality drugs. Addressing the systemic vulnerabilities in drug regulation requires robust collaboration between the Union and state governments. Centralized information systems, enhanced legal powers for states, and a unified strategy to combat NSQ drugs will be pivotal in ensuring the safety and well-being of citizens.
